Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

NCT01766778 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Type-2 Diabetes Mellitus

Interventions

DRUG: LAF237 (vildagliptin)
DRUG: Metformin

Sponsor

Novartis Pharmaceuticals